

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q83534

Andrew Lennard LEWIS, et al.

Appln. No.: 10/506,805

Group Art Unit: 1611

Confirmation No.: 5416

Examiner: Kyle A PURDY

Filed: January 19, 2005

For: DRUG CARRIERS COMPRISING AMPHIPHILIC BLOCK COPOLYMERS

STATEMENT OF SUBSTANCE OF INTERVIEW

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please review and enter the following remarks summarizing the interview conducted on

July 27, 2010:

REMARKS

During the interview, the following was discussed:

1. Brief description of exhibits or demonstration: None
2. Identification of claims discussed: Pending claims
3. Identification of art discussed: Dahms
4. Identification of principal proposed amendments: None
5. Brief Identification of principal arguments: Applicant discussed with the

Examiner the differences between Dahms and the present claims, including the differences in cytotoxicity between the two.

6. Indication of other pertinent matters discussed: None

7. Results of Interview: Applicant indicated that they would consider the Examiner's comments when preparing a supplemental response.

It is respectfully submitted that the instant STATEMENT OF SUBSTANCE OF INTERVIEW complies with the requirements of 37 C.F.R. §§1.2 and 1.133 and MPEP §713.04.

It is believed that no petition or fee is required. However, if the USPTO deems otherwise, Applicant hereby petitions for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,



Travis B. Ribar
Registration No. 61,446

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: October 6, 2010